Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELMD Electromed	$18.93 -1.3%	$19.68	$13.74 ▼ $35.56	$158.75M	0.38	83,048 shs	63,582 shs
LNSR LENSAR	$12.65 +1.2%	$12.86	$3.80 ▼ $17.31	$149.18M	0.5	57,859 shs	63,957 shs
NMTC NeuroOne Medical Technologies	$0.82 -1.2%	$0.74	$0.40 ▼ $1.39	$41.35M	0.68	239,240 shs	94,732 shs
TLSI TriSalus Life Sciences	$4.55 +17.3%	$4.78	$3.42 ▼ $6.03	$146.82M	0.48	76,554 shs	141,396 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELMD Electromed	-1.25%	+1.56%	+2.77%	-12.16%	+31.92%
LNSR LENSAR	+1.20%	-1.71%	-3.73%	-10.35%	+215.46%
NMTC NeuroOne Medical Technologies	-1.23%	+9.51%	+13.31%	+23.28%	+10.63%
TLSI TriSalus Life Sciences	+17.27%	+15.19%	-3.40%	-11.48%	-22.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELMD Electromed	1.3463 of 5 stars	2.0	3.0	0.6	1.7	1.3
LNSR LENSAR	0.6732 of 5 stars	2.0	1.0	1.0	2.5	0.0
NMTC NeuroOne Medical Technologies	2.7243 of 5 stars	3.5	5.0	2.4	0.8	0.0
TLSI TriSalus Life Sciences	3.0774 of 5 stars	3.6	3.0	2.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELMD Electromed	4.00	Strong Buy	$33.50	76.97% Upside
LNSR LENSAR	2.00	Hold	$15.00	18.58% Upside
NMTC NeuroOne Medical Technologies	3.00	Buy	$1.45	76.87% Upside
TLSI TriSalus Life Sciences	3.25	Buy	$10.75	136.26% Upside

Current Analyst Ratings Breakdown

Latest NMTC, TLSI, ELMD, and LNSR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/22/2025	ELMD Electromed	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$29.00
7/21/2025	ELMD Electromed	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELMD Electromed	$61.44M	2.58	$0.46 per share	41.36	$5.10 per share	3.71
LNSR LENSAR	$53.49M	2.82	N/A	N/A	($1.93) per share	-6.55
NMTC NeuroOne Medical Technologies	$3.45M	11.84	N/A	N/A	$0.03 per share	27.33
TLSI TriSalus Life Sciences	$29.43M	5.85	N/A	N/A	($0.51) per share	-8.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELMD Electromed	$5.15M	$0.79	25.24	∞	N/A	11.34%	15.71%	13.37%	N/A
LNSR LENSAR	-$31.40M	-$4.21	N/A	∞	N/A	-84.49%	-737.30%	-72.60%	N/A
NMTC NeuroOne Medical Technologies	-$12.32M	-$0.22	N/A	∞	N/A	-55.44%	-327.95%	-98.12%	N/A
TLSI TriSalus Life Sciences	-$30.05M	-$1.18	N/A	N/A	N/A	-86.61%	N/A	-116.50%	N/A

Latest NMTC, TLSI, ELMD, and LNSR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q3 2025	NMTC NeuroOne Medical Technologies	-$0.05	-$0.03	+$0.02	-$0.03	$1.82 million	$1.70 million
8/12/2025	Q2 2025	TLSI TriSalus Life Sciences	-$0.22	-$0.27	-$0.05	-$0.27	$10.69 million	$11.21 million
8/7/2025	Q2 2025	LNSR LENSAR	-$0.0750	-$0.15	-$0.0750	-$0.15	$16.55 million	$11.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELMD Electromed	N/A	N/A	N/A	N/A	N/A
LNSR LENSAR	N/A	N/A	N/A	N/A	N/A
NMTC NeuroOne Medical Technologies	N/A	N/A	N/A	N/A	N/A
TLSI TriSalus Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELMD Electromed	N/A	5.10	4.74
LNSR LENSAR	N/A	1.52	0.88
NMTC NeuroOne Medical Technologies	N/A	2.13	1.09
TLSI TriSalus Life Sciences	N/A	4.08	1.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELMD Electromed	40.82%
LNSR LENSAR	40.15%
NMTC NeuroOne Medical Technologies	16.07%
TLSI TriSalus Life Sciences	2.58%

Insider Ownership

Company	Insider Ownership
ELMD Electromed	14.00%
LNSR LENSAR	38.52%
NMTC NeuroOne Medical Technologies	8.90%
TLSI TriSalus Life Sciences	27.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELMD Electromed	160	8.39 million	7.36 million	Optionable
LNSR LENSAR	110	11.94 million	7.34 million	Optionable
NMTC NeuroOne Medical Technologies	20	49.82 million	45.38 million	Optionable
TLSI TriSalus Life Sciences	106	37.84 million	27.43 million	Not Optionable

NMTC, TLSI, ELMD, and LNSR Headlines

Recent News About These Companies

FY2025 EPS Estimates for TLSI Boosted by Cantor Fitzgerald

2 hours ago | americanbankingnews.com

TriSalus Life Sciences (NASDAQ:TLSI) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS

August 14 at 6:29 PM | marketbeat.com

TriSalus Life Sciences Reports Strong Growth Amid Challenges

August 14 at 2:19 AM | msn.com

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q2 2025 Earnings Call Transcript

August 14 at 2:19 AM | msn.com

TriSalus Life Sciences Reports Strong Q2 2025 Growth

August 13 at 6:20 AM | msn.com

TriSalus Life Sciences, Inc. (TLSI) Q2 2025 Earnings Call Transcript

August 12, 2025 | seekingalpha.com

TriSalus Life Sciences backs FY25 revenue growth view up 50%

August 12, 2025 | msn.com

TriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue Estimates

August 12, 2025 | zacks.com

TriSalus Life Sciences (TLSI) Expected to Announce Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

July 30, 2025 | businesswire.com

TriSalus Life Sciences (NASDAQ:TLSI) Stock Price Down 4.6% - Should You Sell?

July 30, 2025 | marketbeat.com

TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call

July 29, 2025 | businesswire.com

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock

July 24, 2025 | businesswire.com

TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System - Business Wire

June 25, 2025 | businesswire.com

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

June 23, 2025 | businesswire.com

TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience

May 30, 2025 | businesswire.com

Jodi Devlin Sells 4,764 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Stock

May 22, 2025 | insidertrades.com

TriSalus outlines at least 50% revenue growth for 2025 as new Medicare code expands addressable market

May 15, 2025 | msn.com

TriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call Transcript

May 15, 2025 | seekingalpha.com

TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates

May 15, 2025 | zacks.com

TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance

May 15, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMTC, TLSI, ELMD, and LNSR Company Descriptions

Electromed NYSE:ELMD

$18.93 -0.24 (-1.25%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$18.86 -0.07 (-0.34%)

As of 08/15/2025 04:04 PM Eastern

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.

LENSAR NASDAQ:LNSR

$12.65 +0.15 (+1.20%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$13.22 +0.57 (+4.54%)

As of 08/15/2025 05:52 PM Eastern

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

NeuroOne Medical Technologies NASDAQ:NMTC

$0.82 -0.01 (-1.23%)

Closing price 08/15/2025 03:54 PM Eastern

Extended Trading

$0.80 -0.02 (-2.42%)

As of 08/15/2025 05:28 PM Eastern

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.

TriSalus Life Sciences NASDAQ:TLSI

$4.55 +0.67 (+17.27%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$4.60 +0.04 (+0.99%)

As of 08/15/2025 07:51 PM Eastern

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time